Yousen Jianheng develops medicines for cancer and autoimmune diseases.
Established in 2020 and based in Shanghai, China, Yousen Jianheng develops first-in-class and best-in-class medicines. Its research includes small-molecule drugs, recombinant proteins, and single or dual antibodies for cancer and autoimmune diseases. In February 2022, it raised over CNY 200 million in Series A funding; its UA007 program was in Phase II trials for cardiovascular disease and Phase I trials for acute gout.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign inWork at Yousen Jianheng Biomedical (Shanghai) Co., Ltd.? This is my company